Sensex, Nifty Hit Seven-Week High Ahead of RBI Policy, IT and Bank Stocks Lead
Sandip Raj Gupta
05/Dec/2024

What's Covered:
- Sensex and Nifty surged 1% each, reaching levels last seen on October 15, ahead of the RBI policy.
- IT, banking, and auto stocks led the rally, with Infosys and TCS climbing over 3% each.
- Key stock movements included Aurobindo Pharma's US FDA approval and Adani Energy's new order win.
The Indian equity markets continued their rally for the fifth straight session on December 5, 2024, with Sensex and Nifty closing at a seven-week high. Investors remain optimistic ahead of the Reserve Bank of India’s (RBI) monetary policy announcement, driven by expectations of rate cuts and liquidity measures.
Market Overview
The Sensex surged by 809 points (1%) to close at 81,765.86, while the Nifty rose by 240.95 points (1%) to end at 24,708.40. Broader markets also posted gains:
- The BSE MidCap index rose for the ninth time in ten sessions.
- The SmallCap index recorded its tenth consecutive session of gains.
Market breadth remained strong, with 2,144 stocks advancing, 1,821 declining, and 118 unchanged. The India VIX climbed 0.5% to 14.53, reflecting slightly increased volatility.
Key Sectoral Performances
- The Nifty IT index emerged as the best performer, rising 2%, led by gains in Infosys and TCS.
- Nifty Auto, Private Banks, and Oil & Gas advanced 0.7%-0.8% each.
- On the downside, Nifty Realty fell 0.2%, and Nifty PSU Bank slipped 0.1%.
Key Gainers and Losers
Technology and financial stocks dominated the gains:
- Infosys and TCS surged over 3%, while Titan rose 2.8%.
- Bajaj Finance, M&M, ICICI Bank, and Bharti Airtel added 1.9% each.
- NTPC was the only Sensex stock to decline, falling 0.5%.
Stock-Specific Updates
Aurobindo Pharma
The company's subsidiary, Eugia Pharma, received US FDA approval to manufacture and market Pazopanib Tablets, a treatment for advanced renal cell carcinoma and soft tissue sarcoma. The product is expected to launch in Q4FY25 and has an estimated market size of Rs 898 crore.
Torrent Pharmaceuticals
Torrent Pharma entered an agreement with Boehringer Ingelheim to acquire three diabetes-related brands—Cospiaq, Cospiaq Met, and Xilingio. These brands are projected to expand Torrent’s presence in the diabetes market, which has an estimated size of Rs 3,235 crore.
Adani Energy Solutions
The company received a Letter of Intent (LoI) to establish a power transmission system for evacuating power from Rajasthan's Renewable Energy Zone under Phase-III Part-I.
KIOCL
KIOCL resumed operations at its pellet manufacturing plant in Mangalore, signaling positive operational developments.
NBCC (India)
NBCC's subsidiary, HSCC (India), secured orders worth Rs 599.4 crore from the National Health Mission in Maharashtra, which includes radiation oncology units and other projects.
Zomato
The food delivery giant surged to a 52-week high of Rs 304.6 after Bernstein assigned an ‘Outperform’ rating with a target price of Rs 335, citing higher gross order value and broader city presence compared to Swiggy.
PG Electroplast
The stock hit an all-time high of Rs 825 as the board approved a qualified institutional placement (QIP) of equity shares worth Rs 1,500 crore at a floor price of Rs 705.2 per share.
Bondada Engineering
Bondada Engineering received a Rs 108.9 crore order from the Bihar Renewable Energy Development Agency for a solar streetlight project under the Mukhyamantri Gramin Solar Street Light Yojana.
Bharat Forge
The board of Bharat Forge approved a QIP of equity shares worth Rs 1,650 crore, boosting investor confidence.
Indraprastha Gas
The company’s board plans to meet on December 10, 2024, to consider issuing bonus shares to shareholders, driving stock momentum.
Marico
Marico appointed Ashish Goupal as the new CEO of its India core business, effective April 1, 2025, signaling leadership continuity.
Lemon Tree Hotels
Lemon Tree secured an order to redevelop and operate the Orchid Hotel in Shillong, enhancing its portfolio in India.
Muthoot Microfin
Muthoot Microfin reduced lending rates on income-generating loans by 25 bps to 23.1% and third-party product loans by 125 bps to 22.7%, marking its third rate cut this year.
Global and Domestic Factors
The rally was supported by a mix of global and domestic factors:
- Positive global cues from European and US markets supported sentiment, while Brent crude oil prices edged higher ahead of the OPEC+ meeting.
- Domestically, expectations of a 25 bps rate cut by the RBI fueled optimism, supported by a Nomura report predicting 100 bps cuts by mid-2025.
Outlook
With IT and financial stocks driving gains, coupled with optimism around the RBI’s upcoming policy meeting, the market is well-positioned for further upward momentum. Broader market participation and strong sectoral performances are expected to continue, making Indian equities an attractive proposition for investors.
The Upcoming IPOs in this week and coming weeks are Dhanlaxmi Corp, Jungle Camps, Toss The Coin, Purple United, Rosmerta Digital and Avanse Financial.The Current active IPO is Nisus Finance and Emerald Tyre Manufacturers.
For more details on upcoming IPOs, you can visit our page at Best IPO to Apply Now - IPO List 2024, Latest IPO, Upcoming IPO, Recent IPO News, Live IPO GMP Today - Finance Saathi and stay updated with the latest news on IPO updates on Top News Headlines - Share Market News, Latest IPO News, Business News, Economy News - Finance Saathi.Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.Start your Stock Market Journey and Apply in IPO by opening a Free Demat Account in Choice Broking FinX.
Related News
Disclaimer
The information provided on this website is for educational and informational purposes only and should not be considered as financial advice, investment advice, or trading recommendations.
Trading in stocks, forex, commodities, cryptocurrencies, or any other financial instruments involves high risk and may not be suitable for all investors. Prices can fluctuate rapidly, and there is a possibility of losing part or all of your invested capital.
We do not guarantee any profits, returns, or outcomes from the use of our website, services, or tools. Past performance is not indicative of future results.You are solely responsible for your investment and trading decisions. Before making any financial commitment, it is strongly recommended to consult with a qualified financial advisor or do your own research.
By accessing or using this website, you acknowledge that you have read, understood, and agree to this disclaimer. The website owners, partners, or affiliates shall not be held liable for any direct or indirect loss or damage arising from the use of information, tools, or services provided here.